Treosulfan as an effective second-line therapy in ovarian cancer;Treosulfan als effiziente Second-line-Therapie beim Ovarialkarzinom

Geburtshilfe und Frauenheilkunde

Volumn 57, Issue 6, 1997, Pages 356-360

  Gropp, M ^a,b   Meier, W ^a   Hepp, H ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Klin Poliklin F F   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TREOSULFAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; QUALITY OF LIFE; SURVIVAL;

EID: 0030761710     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023097     Document Type: Article

References (31)

1. Anderson, B.: Quality of life in progressive ovarian cancer. Gynecol. Oncol. 55 (1994) 151-155.
2. Du Bois, A.: Chemotherapie beim Platin-refraktären Ovariaikarzinom. In Seeber, S., H.-G. Meerpohl. H. Kühnle, K. Diergarten (Hrsg.): Aktuelle Onkologie 92, Taxol. Zuckschwerdt-Verlag, München (1996) 1-19.
3. Gore, M. E., I. Fryatt, E. Wiltshaw, T. Dawson, B. A. Robinson, A. H. Clavert: Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer 60 (1989) 767-769.
4. Guidozzi, F.: Living with ovarian cancer. Gynecol. Oncol. 50 (1993) 202-207.
5. Hoskins, P. J., K. D. Swenerton: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 60-63.
6. Jänicke, F., M. Hölscher, W. Kuhn, R. v. Hugo, L. Pache, J. R. Siewert, H. Graeff: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70 (1992) 2129-2136.
7. Kaplan, E. L., P. Meier: Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 53 (1958) 457-481.
8. Kavanagh, J. J., D. Treskosol, G. De Leon et al.: Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int. J. Gynecol. Cancers (1995) 351-354.
9. Kudelka, A., C. Edwards, R. Freedman et al.: A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma. Proc. ECCO 7 (1993) abstr. 722.
10. Kühnle, H., W. Achterrath, R. Frischkorn: Krankheitsorientierte Phase II Studie mit Etoposid (NSC 141540) bei cisplatin-refraktä-ren Ovarialkamnomen. Tumordiagn. Ther. 5 (1984) 152-155.
11. Kühnle, H., L Lenaz, H. G. Meerpohl et al.: Etoposide in cisplatin-refractory ovarian cancer. Proc. Amer. Soc. Clin. Oncol. 7 (1988) 527.
12. Kuhn, W., F. Jänicke, L. Pache, M. Hölscher, G. Schattenmann, B. Schmalfeldt, H. Anderl, G. Schüle, P. Dettnar, J. R. Siewert, H. Graeff: Entwicklung in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtsh. u. Frauenheilk. 53 (1993) 293-302.
13. Kuhn, W., B. Schmalfeldt, J. Dose, L Pache, K. Freitag, K. Freitag, F. Janicke, H. Graeff: Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs. Geburtsh. u. Frauenheilk. 56 (1996) 105-110.
14. Markman, M., R. Rothman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadrones, J. L. Lewis: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393.
15. Markman, M., T. Hakes, B. Reichman, J. L. Lewis jr., S. Rubin, W. Jones, L. Almadrones, F. Pizzuto, W. Hoskins: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 10 (1992) 243-248.
16. Markman, M., T. Hakes, B. Reichman et al.: Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J. Cancer Res. Clin. Oncol. 119 (1992) 55-57.
17. Marth, C., E. Pointner, A. G. Zeimet, E. Abfalter, A. Kozza, G. Windbickler, H. Hetzel, O. Dapunt: Die Wertigkeit von Etoposid (VP-16) in der Therapie des refraktären Ovarialkarzinoms. Geburtsh. u. Frauenheilk. 53 (1993) 303-307.
18. Meier, W., M. Römisch, H. Hepp: Stellenwert der Rezidivchirurgie in der Behandlung des Ovarialkarzinoms. Geburtsh. u. Frauenheilk. 53 (1993) 30-34.
19. Pfleiderer, A., H. Meerpohl: Standard der Chemotherapie beim Ovarialkarzinom. Chirurg 65 (1994) 1-5.
20. Repetto, L. S. Chiara, S. Mammoliti et al.: Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecol. Oncol. 39 (1990) 146-149.
21. Segna, R. A., P. R. Dottino, J. P. Mandeli, K. Konsker, C. J. Cohen: Secondary cytoreduction for ovarian cancer following cispiatin therapy. J. Clin. Oncol. 11 (1993) 434-439.
22. Sinha, B.: Topoisomerase inhibitors. Drugs 49 (1995) 11-19.
23. Sutton, G.: Secondary therapy for epithelial ovarian cancer - 1994. Semin. Oncol. 21,4 (1994) 32-36.
24. Thigpen, J. T., W. P. McGuire, W. J. Hoskins, M. F. Brady: Paclitaxel: current and future role in epithelial ovarian cancer. Abstract. New directions in anti-cancer chemotherapy. Symposium Paris, 31.1.1995, Bristol-Myers Squibb 14-15.
25. Trimble, E., J. Adams, D. Vena, M. Hawkins, M. Friedman, J. Fisherman, M. Christian, R. Canetta, N. Onetto, R. Hayn, S. Arbuch: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to NCI treatment referral center 9103. J. Clin. Oncol. 11,12 (1993) 2405-2410.
26. Tropé, C., J. Kaern, I. Vergote, S. Vossli: A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemoth. Pharm. 26, suppl. (1990) 45-47.
27. Uziely, B., S. Groshen, S. Jeffers, M. Morris, C. Russell, L. Roman, L. Muderspach, F. Muggia: Paclitaxel (Taxol) in heavily pretreated ovarian cancer: Antitumor activity and complications. Ann. Oncol. 5 (1994) 8827-8833.
28. Vergote, I., A. Himmelmann, B. Frankendal, M. Scheistroen, K. Vlachos, C. Trepé: Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol. Oncol. 47 (1992) 282-286.
29. Vermorken, J. B., A. Kobierska, F. Chevallier, F. Zanaboni, A. Pawinski, G. Bolis: Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin. Proc. Amer. Soc. Clin. Oncol. 14 (1995) 276 (abstr. 772).
30. WHO: WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication. No. 48 (1979).
31. de Wit, R., M. E. L. van der Burg, A. v. d. Gaast, A. Logmans, G. Stoter, J. Verweij: Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum containing chemotherapy. Ann. Oncol. 5 (1994) 656-657.